[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100663115":3},{"organization":4,"outcomesModule":7,"designInfo":63,"detailedDescription":71,"studyPopulation":68,"armGroups":72,"interventions":83,"overallOfficials":89,"centralContacts":96,"locations":68,"responsibleParty":103,"collaborators":105,"id":108,"slug":109,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":110,"sex":116,"minAge":117,"maxAge":68,"enrollmentInfo":118,"targetDuration":68,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":131,"whyStopped":68,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":68},{"fullName":5,"class":6},"Region Stockholm","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":53},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in the proportion of patients with blood pressure \u003C130\u002F\u003C80 mmHg","Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals whose last recorded blood pressure was below the target according to the person-centered and integrated care pathway (PSVF) for hypertension (\\\u003C130\u002F\\\u003C80 mmHg), irrespective of measurement method (office, home, or ambulatory blood pressure monitoring). The outcome is assessed in each 6-month interval, and the primary effect measure is the average effect over the first 12 months after each center's scheduled crossover.","6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods",[14,17,20,23,26,29,32,35,38,41,44,47,50],{"measure":15,"description":16,"timeFrame":12},"Change from baseline in the proportion of patients with their blood pressure measured","Proportion of patients with a diagnosis of hypertension who, in each 6-month interval had their blood pressure measured",{"measure":18,"description":19,"timeFrame":12},"Change from baseline in the proportion of patients who were dispensed statin therapy","Proportion of patients with a diagnosis of hypertension who were dispensed statin therapy",{"measure":21,"description":22,"timeFrame":12},"Change from baseline in the proportion of patients who achieved an office blood pressure \u003C140\u002F\u003C90 mmHg, a home blood pressure \u003C135\u002F\u003C85 mmHg, or an ambulatory blood pressure \u003C135\u002F\u003C85 mmHg","Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals who achieved an office blood pressure \\\u003C140\u002F\\\u003C90 mmHg, a home blood pressure \\\u003C135\u002F\\\u003C85 mmHg, or an ambulatory blood pressure \\\u003C135\u002F\\\u003C85 mmHg. The outcome is assessed in each 6-month interval, and the effect measure is the average effect over the first 12 months after each center's scheduled crossover.",{"measure":24,"description":25,"timeFrame":12},"Change from baseline in the proportion of patients who were dispensed combination therapy with antihypertensive agents","Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in the 6-month interval who were dispensed combination therapy with antihypertensive agents (2, 3, or more)",{"measure":27,"description":28,"timeFrame":12},"Change from baseline in the proportion of patients who achieved LDL cholesterol targets according to the ESC guidelines","Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in the 6-month interval who achieved LDL cholesterol targets according to the ESC guidelines (among patients with LDL cholesterol measured). Very high risk \\\u003C1.4 mmol\u002FL; high risk \\\u003C1.8 mmol\u002FL, moderate risk \\\u003C2.6 mmol\u002FL).",{"measure":30,"description":31,"timeFrame":12},"Observed population trajectory of the proportion of patients with hypertension below 130\u002F80 mmHg","Observed population trajectory describing the proportion of patients with hypertension below the PSVF target 130\u002F80 mmHg per half-year from H1-2025 to H2-2028, using the last blood pressure in that half-year. If no measurement is recorded, the most recent value during the last 12 months is carried forward. Missing values will be regarded as not treated to target. This is a descriptive series with no model terms and no p-values. It shows the total change in the population, combining the secular trend and the rollout.",{"measure":33,"description":34,"timeFrame":12},"Change from baseline in proportion of patients with uncontrolled blood pressure that received treatment intensification","Proportion of patients with a diagnosis of hypertension and a last blood pressure \\>= 130\u002F80 mmHg in the 6-month interval who were dispensed combination therapy with antihypertensive agents (2, 3, or more)",{"measure":36,"description":37,"timeFrame":12},"Change in last measured systolic BP in mmHg per patient period","Mean systolic blood pressure in patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals. The outcome is assessed in each 6-month interval, and the effect measure is the average effect over the first 12 months after each center's scheduled crossover.",{"measure":39,"description":40,"timeFrame":12},"Mean number of primary care contacts per patient","Resource utilization. Mean number of primary care contacts per patient per 6-month interval, by staff category, in total and with a hypertension diagnosis registered at the visit. Reported descriptively per sequence and period.",{"measure":42,"description":43,"timeFrame":12},"Mean number of laboratory tests per patient","Resource utilization. Mean number of laboratory tests (creatinine, potassium, sodium, lipids) per patient per 6-month interval. Reported separately for each test type. Reported descriptively per sequence and period.",{"measure":45,"description":46,"timeFrame":12},"Mean number of blood pressure measurements per patient","Resource utilization. Mean number of blood pressure measurements per patient per 6-month interval, by measurement type. Reported by measurement type (office, home, ambulatory). Reported descriptively per sequence and period.",{"measure":48,"description":49,"timeFrame":12},"Mean dispensed defined daily doses (DDDs) per patient","Resource utilization. Mean dispensed defined daily doses (DDDs) of antihypertensives and statins per patient per 6-month interval. Reported separately for antihypertensive agents and statins. Reported descriptively per sequence and period.",{"measure":51,"description":52,"timeFrame":12},"Mean pharmacy cost per patient","Resource utilization. Mean pharmacy cost of dispensed antihypertensives and statins per patient per 6-month interval. Reported separately for antihypertensive agents and statins. Reported descriptively per sequence and period.",[54,58,61],{"measure":55,"description":56,"timeFrame":57},"Adverse drug reactions related to antihypertensive medication","Safety outcome. Adverse drug reactions related to antihypertensive medication: acute kidney injury, hypotension or syncope, orthostatic hypotension, and fall injury. Based on hospitalizations with relevant ICD-10 codes.","First event per patient and 6-month interval, analyzed as event rates per person-time and reported as a rate ratio averaged over the first 12 months after crossover",{"measure":59,"description":60,"timeFrame":57},"Myocardial infarction and stroke","Hypertension-related complications: myocardial infarction and stroke",{"measure":62,"description":62,"timeFrame":57},"All-cause mortality",{"allocation":64,"interventionModel":65,"interventionModelDescription":66,"primaryPurpose":67,"observationalModel":68,"timePerspective":68,"maskingInfo":69},"RANDOMIZED","CROSSOVER","Stepped-wedge cluster randomized trial of 16 primary care centers in 4 sequences for a total of 64 centers.","TREATMENT",null,{"masking":70,"maskingDescription":68,"whoMasked":68},"NONE","Intervention: Information and educational initiatives on the national care pathway for hypertension, including specific recommendations regarding treatment and the use of digital support tools Study sites: Publicly funded primary care centers within Stockholm Region (SLSO) Study period: Primary analysis covering 2025-2028. Data extraction covering the period 2020-2028 Design: Stepped-wedge cluster-randomized trial Number of study units: Sixteen primary care centers will receive the intervention every 6 months during the period January 2027 to December 2028, for a total of 64 primary care centers.\n\nCondition: Hypertension\n\nInclusion criteria: Publicly funded primary care centers within Stockholm Region (SLSO)\n\nExclusion criteria: Not applicable\n\nControl group: Primary care centers that have not yet received the intervention serve as controls until they receive the intervention.\n\nDefinition of hypertension: Listed patients 18 years or above with a diagnosis of hypertension (ICD-10 I10-I15) during the last five years\n\nPre-defined subgroup analyses: Sex and age group (18-79, 80+ years)",[73,79],{"label":74,"type":75,"description":76,"interventionNames":77},"Intervention","EXPERIMENTAL","Educational intervention for doctors and nurses.",[78],"Other: Educational intervention for doctors and nurses",{"label":80,"type":81,"description":82,"interventionNames":68},"Control","NO_INTERVENTION","Control arm where each primary care unit is considered a control prior to the intervention",[84],{"type":85,"name":86,"description":87,"armGroupLabels":88,"otherNames":68},"OTHER","Educational intervention for doctors and nurses","Educational intervention for doctors and nurses. Information and educational initiatives on the national care pathway for hypertension, including specific recommendations regarding treatment and the use of digital support tools. The intervention consists of in-person lectures by a physician educator, combined with an information package for physicians, nurses and patients. This includes standardised treatment algorithms with early combination therapy. Educational material will be made available electronically. Primary care centers will be provided with tools for continuous monitoring of their performance.",[74],[90,94],{"name":91,"affiliation":92,"role":93},"Tomas Forslund, MD PhD","Region Stockholm, Karolinska Institutet","PRINCIPAL_INVESTIGATOR",{"name":95,"affiliation":92,"role":93},"Jonas Spaak, MD PhD",[97,101],{"name":91,"role":98,"phone":99,"phoneExt":68,"email":100},"CONTACT","+46(0)812355000","tomas.forslund.1@ki.se",{"name":95,"role":98,"phone":99,"phoneExt":68,"email":102},"jonas.spaak@ki.se",{"type":104,"investigatorFullName":68,"investigatorTitle":68,"investigatorAffiliation":68,"oldNameTitle":68,"oldOrganization":68},"SPONSOR",[106],{"name":107,"class":85},"Karolinska Institutet","100663115","implementation-of-a-person-centered-and-integrated-care-pathway-for-hypertension-100663115",false,"NCT07914283","Implementation of a Person-Centered and Integrated Care Pathway for Hypertension","Implementation of a Person-Centered and Integrated Care Pathway for Hypertension: a Cluster-Randomized Trial","IMPLEMENT-HT","Inclusion Criteria:\n\nPublicly funded primary care centers within Stockholm Region (SLSO)\n\nExclusion Criteria:\n\nNot applicable","ALL","18 Years",{"count":119,"type":120},120000,"ESTIMATED","INTERVENTIONAL",[123],"NA","The aim is to investigate whether information and educational initiatives on the Swedish national care pathway for hypertension, directed at primary care centers, lead to an increase in the proportion of patients achieving target blood pressure.",[126],"Hypertension",[128,129,130],"Cluster randomized trial","Stepped-wedge cluster-randomized trial","Educational intervention","NOT_YET_RECRUITING","2026-10-28",{"date":134,"type":135},"2026-11-03","ACTUAL",{"date":137,"type":120},"2027-01-01",{"date":139,"type":120},"2028-12-31",{"name":5,"class":6}]